The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Retrospective evaluation of RET biomarker status and outcome to vandetanib in four phase III randomized NSCLC trials.
Adam Platt
Employment or Leadership Position - AstraZeneca
Paul Elvin
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Research Funding - AstraZeneca
John Morten
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Qunsheng Ji
Employment or Leadership Position - AstraZeneca
Emma Donald
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Chris Womack
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Xinying Su
Employment or Leadership Position - AstraZeneca
Li Zheng
Employment or Leadership Position - AstraZeneca
Amanda Gladwin
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
James Robert Vasselli
Employment or Leadership Position - AstraZeneca
Stock Ownership - AstraZeneca
Jin Soo Lee
Research Funding - AstraZeneca
Richard H. De Boer
Consultant or Advisory Role - AstraZeneca
Honoraria - AstraZeneca
Research Funding - AstraZeneca
Roy S. Herbst
No relevant relationships to disclose